Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10774512 | 0.91 | SLC6A4 (0.63) | SLC6A4MAOATAAR1 | |
| SCHEMBL10772813 | 0.91 | SLC6A4 (0.63) | SLC6A4MAOATAAR1 | |
| SCHEMBL10771733 | 0.91 | SLC6A4 (0.63) | SLC6A4MAOATAAR1 | |
| SCHEMBL9649838 | 0.87 | SLC6A4 (0.59) | SLC6A4TAAR1 | |
| SCHEMBL9649844 | 0.87 | SLC6A4 (0.59) | SLC6A4TAAR1 | |
| SCHEMBL9651013 | 0.87 | SLC6A4 (0.59) | SLC6A4TAAR1 | |
| SCHEMBL5018832 | 0.85 | KDM4E (0.53) | ACACB | |
| SCHEMBL2553015 | 0.85 | SLC6A4 (0.66) | SLC6A4MAOATAAR1 | |
| SCHEMBL2553013 | 0.85 | SLC6A4 (0.66) | SLC6A4MAOATAAR1 | |
| SCHEMBL10562624 | 0.84 | SLC6A4 (0.56) | SLC6A4MAOAMAOBTAAR1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2012-01-19 | — | — | US | disclosed |
| US-7956220-B2 | MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY (US) | 2011-06-07 | — | — | US | disclosed |
| WO-2007005845-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | SLC6A4 467/4885MAOA 2/4885MAOB 1/4885 |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | SLC6A4 467/4885MAOA 2/4885MAOB 1/4885 |
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | SLC6A4 467/4885MAOA 2/4885MAOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.